Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

BIO VP-Health Policy Cohen Joins From HIAA To Handle Medicare Rx Policy

  • News

Executive Summary

The Biotechnology Industry Organization is gearing up for a more active role in the Medicare Rx debate in 2001 by recruiting HIAA chief lobbyist Sharon Cohen to serve as VP-health policy.

You may also be interested in...



BIO Government Relations VP Cohen Moving To PodestaMattoon

Biotechnology Industry Organization VP-Government Relations Sharon Cohen is joining the lobbying firm of PodestaMattoon

BIO Government Relations VP Cohen Moving To PodestaMattoon

Biotechnology Industry Organization VP-Government Relations Sharon Cohen is joining the lobbying firm of PodestaMattoon

BIO Government Relations To Be Headed By Cohen As Rawls Moves To FBI

Biotechnology Industry Organization VP-Health Policy Sharon Cohen will head the association's government relations department following the departure of VP-Government Relations Lee Rawls, BIO announced Nov. 28

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

See All
UsernamePublicRestriction

Register

PS037172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By